Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy ; volume:13 ; number:1 ; year:2020 ; pages:271-275
Case reports in oncology ; 13, Heft 1 (2020), 271-275
- Urheber
-
Fujimura, Taku
Kambayashi, Yumi
Ohuchi, Kentaro
Amagai, Ryo
Sato, Yota
Tanita, Kayo
Hashimoto, Akira
Aiba, Setsuya
- DOI
-
10.1159/000506327
- URN
-
urn:nbn:de:101:1-2020051401014167996448
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fujimura, Taku
- Kambayashi, Yumi
- Ohuchi, Kentaro
- Amagai, Ryo
- Sato, Yota
- Tanita, Kayo
- Hashimoto, Akira
- Aiba, Setsuya
Ähnliche Objekte (12)
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy